CARDIOPROOF

Proof of Concept of Model-based Cardiovascular Prediction

 Coordinatore  

 Organization address address: LIVENZA 6
city: ROME
postcode: 198

contact info
Titolo: Dr.
Nome: Mirko
Cognome: De Maldè
Email: send email
Telefono: +39 068440801
Fax: +39 0685344833

 Nazionalità Coordinatore Non specificata
 Totale costo 5˙891˙930 €
 EC contributo 4˙107˙000 €
 Programma FP7-ICT
Specific Programme "Cooperation": Information and communication technologies
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2016-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    LYNKEUS

 Organization address address: LIVENZA 6
city: ROME
postcode: 198

contact info
Titolo: Dr.
Nome: Mirko
Cognome: De Maldè
Email: send email
Telefono: +39 068440801
Fax: +39 0685344833

IT (ROME) coordinator 0.00
2    DEUTSCHES HERZZENTRUM BERLIN

 Organization address address: Augustenburger Platz
city: BERLIN
postcode: 13353

contact info
Titolo: Prof.
Nome: Titus
Cognome: Kühne
Email: send email
Telefono: +49 3045932078
Fax: +49 3045932900

DE (BERLIN) participant 0.00
3    ESI GROUP S.A.

 Organization address address: Avenue de Suffren
city: PARIS
postcode: 75015

contact info
Titolo: Dr.
Nome: Argiris
Cognome: Kamoulakos
Email: send email
Telefono: +33 1 41 73 58 00
Fax: +33 1 46 87 72 02

FR (PARIS) participant 0.00
4    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse
city: MUNCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Christoph
Cognome: Schulte
Email: send email
Telefono: +49 89 1205 2728
Fax: +49 89 1205 7534

DE (MUNCHEN) participant 0.00
5    LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE

 Organization address address: Houghton Street
city: LONDON
postcode: WC2A 2AE

contact info
Titolo: Ms.
Nome: Champa
Cognome: Heidbrink
Email: send email
Telefono: +44 2079556840
Fax: +44 2079556803

UK (LONDON) participant 0.00
6    MAAT FRANCE SARL

 Organization address address: IMPASSE DES PRES D EN BAS
city: ARGONAY
postcode: 74370

contact info
Titolo: Dr.
Nome: David
Cognome: Manset
Email: send email
Telefono: +33 45 043 96 02

FR (ARGONAY) participant 0.00
7    MEDIZINISCHE UNIVERSITAT GRAZ

 Organization address address: AUENBRUGGERPLATZ
city: GRAZ
postcode: 8036

contact info
Titolo: Dr.
Nome: Kristina
Cognome: Kofler
Email: send email
Telefono: +43 316 385 71633
Fax: +43 316 385 72030

AT (GRAZ) participant 0.00
8    OSPEDALE PEDIATRICO BAMBINO GESU

 Organization address address: PIAZZA SAN ONOFRIO
city: ROMA
postcode: 165

contact info
Titolo: Dr.
Nome: Sonya Jane
Cognome: Martin
Email: send email
Telefono: +39 06 6859 2497
Fax: +39 06 6859 2101

IT (ROMA) participant 0.00
9    SIEMENS AKTIENGESELLSCHAFT

 Organization address address: Wittelsbacherplatz
city: MUENCHEN
postcode: 80333

contact info
Titolo: Mrs.
Nome: Caroline
Cognome: Wagner-Winter
Email: send email
Telefono: +49 89 636 48325
Fax: +49 89 636 48322

DE (MUENCHEN) participant 0.00
10    UNIVERSITY COLLEGE LONDON

 Organization address address: Gower Street
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 2031083033
Fax: +44 2078132849

UK (LONDON) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

trials    vph    clinical    disease    diagnostics    patient    effectiveness    cardioproof    treatment    predictive    aortic   

 Obiettivo del progetto (Objective)

CARDIOPROOF is a proof-of-concept project that consolidates the outcomes of previous VPH projects and checks the applicability and effectiveness of available predictive modelling and simulation tools, validating them in interrelated clinical trials conducted in three European centres of excellence in cardiac treatment (from Germany, Italy and the UK). CARDIOPROOF focuses on patients with aortic valve disease and aortic coarctation, which, if left untreated, can ensue irreversible heart failure. As a result treatment becomes mandatory, but optimum timing and the best type of treatment still remain difficult to determine. With more than 50.000 interventions per year within the EU, the diseases addressed by CARDIOPROOF have a significant socio-economic impact. Present clinical guidelines are highly complex and rely mostly on imaging diagnostics and clinical parameters, without benefiting, as yet, from patient-specific disease modelling based prediction. CARDIOPROOF goes beyond the current state of the art by conducting validation trials aimed at covering and comparing the complete spectrum of cardiovascular treatment, predicting the evolution of the disease and the immediate and mid-term outcome of treatment. Operational clustering is going to provide a seamless clinical solution that applies different modeling methods to realize the potential of personalised medicine taking into account user-friendliness as a key component of clinical usability. CARDIOPROOF's goal is to provide first-hand data on comparative cost-effectiveness and clinical efficacy of the most advanced VPH approaches compared to conventional diagnostics and treatment algorithms, thus accelerating the deployment of VPH methods in clinical environments, and bring to maturity holistic patient-specific computer-based predictive models and simulations.

Altri progetti dello stesso programma (FP7-ICT)

CRe-AM (2013)

Creativity REsearch Adaptive roadmap

Read More  

E-PRICE (2010)

Price-based Control of Electrical Power Systems

Read More  

CELLULAC (2012)

Commercial production of lactic acid (L and D) from non food lignocellulosic feedstock in a resource efficient biorefinery process

Read More